According to FutureWise analysis, The market for organs on chips is to reach US$ 51 billion in 2022 by FutureWise analysis, and is projected to expand at a CAGR of 30.2% from 2023 to 2031.
Organ-on-chip (OoC) technology is a recent development that benefits from the integration of tissue engineering and stem cells with microfluidics and the microfabrication of sensors and actuators. As an enhancement to current bioassays, OoC models seek to mimic elements of human physiology and pathology in order to shed light on the mechanisms driving drug responses and the onset and progression of the disease. OoC devices may offer more accurate model systems for the study of health and illness, according to growing data. Showcases of vessels-on-chip, cancer-on-chip, kidney-on-chip, neurons, lung-on-chip, and ALS-on-chip are among the examples of the evidence. OoC models are already anticipated to be useful in drug discovery, efficacy, and toxicology, as well as in precision or even personalized medicine with the advent of patient-derived stem cells.
The OoC is a relatively new addition to the toolkit of model biological systems that are available to life science researchers to investigate many facets of human pathophysiology and illness. These systems span a range of physiological significance, with 3D cell cultures, organoids, and OoCs following 2D cell cultures in increasing relevance. Interestingly, using model species like mice and Drosophila to study physiology outperforms using synthetic tissue approaches. Unfortunately, this results in more challenging experiments because biological complexity rises with physiological relevance in model organisms. Despite major advancements in vivo imaging, in vivo physiological processes in mice, humans, and other mammals are often the least amenable to direct examination. The OoC could be seen as a bridging technology that allows for the use of complex cell cultures while also enabling better-tailored microenvironments to enhance the model.
Recent development for Organ-on-Chip Market:
Valo Health acquired TARA Biosystems in April 2022, the business that developed a method for simulating 3D heart tissue. Valo intended to deploy TARA's cardiac tissue chips as a component of an all-encompassing drug development solution focused on cardiovascular disease and driven by its Opal data platform.
The demand for organ-on-chips in drug screening, as well as the demand for lung- and kidney-based organ culture devices, is expected to drive the organ-on-chip market. Furthermore, the scarcity of donor organs and the availability of laboratory-engineered functional organs are expected to be significant advantages in meeting the growing demand for organ transplantation. However, the high cost of organ chip devices, as well as the development of organ-on-chip (OoC) technology, are expected to limit the market growth. Conversely, a significant increase in global healthcare expenditure has led to an increase in the size of the organ-on-chip market. The organ-on-chip market has a lot of potential in emerging economies. Demand for these products is expected to rise in the coming years due to an increase in the number of chronic diseases, high demand for organ transplantation, and an increase in animal testing for drug discovery. The apparatus can also be used to examine the impacts of environmental pollutants, the absorption of therapeutic aerosols, and the security and effectiveness of new medications. Lung-on-chip, which mimics the complex mechanical and biochemical properties of a human lung by combining microfabrication methods with contemporary tissue engineering, also offers a new in-vitro method of drug screening. Such vast application of Ooc is expected to boost the market growth during the forecast period.
FutureWise Market Research has published a report that provides an insightful analysis of Organ-on-Chip market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the Organ-on-Chip market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.